Guardant’s blood test might replace biopsies for some lung cancer patients, study says
In a 282-patient study, the blood test was more likely than a tissue biopsy to match patients with drugs. It was also much faster.
Could a blood test help more lung cancer patients get drugs that are targeted to the genetic weaknesses of their tumors?
Yes, according to summary results of a 282-patient clinical trial being made available Wednesday. The result is a boon for Guardant Health, the San Francisco-based startup that sells the test, Guardant360, which is a “liquid biopsy” that works by detecting fragments of DNA in the bloodstream. The full study will be presented in full at the annual meeting of the American Association for
